← Pacific Biosciences of California overview

Pacific Biosciences of California vs Avantor: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pacific Biosciences of California (PACB)

Q3 2026
▲3▼1

PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares

  • PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.

    This is the main negative force this period, directly lowering revenue expectations and delaying profitability.

  • New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.

    This is a new product improvement that could drive future demand and offset some of the negative guidance.

  • EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.

    This is a new partnership that directly involves PacBio's technology and drove a significant stock move.

  • Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.

    This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.

September 2026
▲3▼1

PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares

  • PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.

    This is the main negative force this period, directly lowering revenue expectations and delaying profitability.

  • New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.

    This is a new product improvement that could drive future demand and offset some of the negative guidance.

  • EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.

    This is a new partnership that directly involves PacBio's technology and drove a significant stock move.

  • Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.

    This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.

Latest
▲3▼1

PacBio cuts outlook, delays breakeven, but new products and partnerships lift shares

  • PacBio slashes 2026 revenue guidance and pushes cash-flow breakeven to 2028 PacBio cut its 2026 revenue forecast to $155–$165 million and now expects cash-flow breakeven in 2028, a year later than planned. The SPRQ-Nx chemistry transition is slower than expected, and instrument demand is weak. This makes the company's path to profitability longer and riskier, pressuring the stock.

    This is the main negative force this period, directly lowering revenue expectations and delaying profitability.

  • New SPRQ-Nx chemistry boosts output and cuts costs for Vega system PacBio announced SPRQ-Nx chemistry and a software update for its Vega sequencer, increasing data output by 50% and cutting cost per gigabase by about 40%. It also adds multiomic capabilities and compliance features. This should make PacBio's products more competitive and attractive to customers, supporting future sales.

    This is a new product improvement that could drive future demand and offset some of the negative guidance.

  • EpiSign-Geneyx partnership incorporates PacBio HiFi sequencing for rare disease analysis EpiSign and Geneyx announced a partnership to integrate genomic and epigenomic analysis for rare diseases, using PacBio HiFi sequencing data. This expands the use of PacBio's platform in clinical research and could lead to more sales. The stock jumped 9.9% on the news, hitting a new 52-week high.

    This is a new partnership that directly involves PacBio's technology and drove a significant stock move.

  • Sampled wins VA contract using PacBio Revio systems Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. This validates PacBio's technology in a large government research setting and could lead to more orders. The stock rose 5.8% on the day.

    This is a new contract that directly benefits PacBio by increasing demand for its Revio systems.

Avantor Inc (AVTR)

Q3 2026
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.

August 2026
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.

Latest
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.